Business
Dr. Jean Bennett and George Migausky Join REGENXBIO Board of Directors
ROCKVILLE, Md., Sept. 7, 2021 /PRNewswire/ -- Renowned gene therapy pioneer and biotechnology executive bring extensive R&D leadership and financial and
About this update from Regenxbio Inc.
[{"type":"text","content":"ROCKVILLE, Md., Sept. 7, 2021 /PRNewswire/ -- \nRenowned gene therapy pioneer and biotechnology executive bring extensive R&D leadership and financial and operational expertise to the BoardREGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Jean Bennett, M.D., Ph.D., and George Migausky to its Board of Directors, effective September 3, 2021. Dr. Bennett, a leading molecular genetics researcher, is the F.M. Kirby Emeritus Professor of Ophthalmology at the Perelman School of Medicine and previously served as director of the Center for Advanced Retinal and Ocular Therapeutics (CAROT) at the University of Pennsylvania. She will serve as a member of REGENXBIO's Nominating and Corporate Governance Committee. Mr. Migausky brings more than 30 years of public company leadership and senior financial management experience. He will serve as a member of REGENXBIO's Audit Committee. \n\"Jean is a renowned and dynamic researcher who has made significant contributions to gene therapy translational studies throughout her career. She was a pioneer in the development of the first FDA-approved gene therapy product, Luxturna®, and continues to collaborate with experts in the field. Her deep expertise, particularly in the field of retinal gene therapy, will make her an invaluable addition to our Board,\" said Allan Fox, Chairman of REGENXBIO's Board of Directors. \"George has significant leadership experience and brings substantial financial management, operational, and business development knowledge and expertise to our Board, including in the field of AAV gene therapy. We look forward to partnering with George and benefiting from the valuable perspective and guidance that he will bring to our Board as we advance our potential one-time gene therapies.\" \n\"REGENXBIO is a leader in the development of gene therapies across a broad range of diseases,\" said Dr. Bennett. \"I am pleased to join the Board at this important time for the company as it advances numerous clinical programs, including the pivotal program for RGX-314, its lead product candidate, for the treatment of wet age-related macular degeneration and the Phase II trial of RGX-314 for the treatment of diabetic retinopathy. I look forward to collaborating with the Board and executive management as we seek to bring important gene therapies to patients.\" \n\"I am honored to join...